Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2024-09-05 DOI:10.1177/11206721241280737

Ecem Önder Tokuç, V Levent Karabaş, Mehmet Orkun Sevik, Fatih Bilgehan Kaplan, Işıl Kutlutürk Karagöz, Hatice Selen Kanar, Uğur Yayla, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Nimet Yeşim Erçalık, Esra Kumral Türkseven, Özlem Aydın Öncü, Erkan Çelik, Ece Başaran Emengen, Abdullah Özkaya, Banu Açıkalın Öncel, Nursal Melda Yenerel, Özlem Şahin

{"title":"Efficacy of ranibizumab and aflibercept on reducing maximum diameter of largest cyst in diabetic cystoid macular edema: MARMASIA study group.","authors":"Ecem Önder Tokuç, V Levent Karabaş, Mehmet Orkun Sevik, Fatih Bilgehan Kaplan, Işıl Kutlutürk Karagöz, Hatice Selen Kanar, Uğur Yayla, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Nimet Yeşim Erçalık, Esra Kumral Türkseven, Özlem Aydın Öncü, Erkan Çelik, Ece Başaran Emengen, Abdullah Özkaya, Banu Açıkalın Öncel, Nursal Melda Yenerel, Özlem Şahin","doi":"10.1177/11206721241280737","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to compare the effect of intravitreal aflibercept (IVA) and ranibizumab (IVR) on the maximal diameter of the largest intraretinal cyst (mdIRC), indicating chronicity in patients with diabetic cystoid macular edema (CME).Methods: This retrospective, comparative study included a subgroup of patients from the MARMASIA Study with treatment-naïve diabetic CME who had IVA (IVA group) or IVR (IVR group) on a pro re nata regimen after a loading dose of 3-monthly injections and followed-up for 24 months. Best-corrected visual acuity (logMAR), central macular thickness (CMT, µm), and mdIRC (µm) and their changes during the study period in the IVA and IVR groups were compared.Results: A total of 175 eyes (65 [37.1%] in IVA and 110 [62.9%] in IVR group) of 113 patients were included in the study analysis. Both groups had statistically significant improvements in BCVA and CMT during the follow-up (p < 0.05 for all), which were comparable between the groups at each time point. However, the mean reduction in mdIRCs was consistently and significantly higher in the IVA group compared to the IVR group at each follow-up examination (F[1, 3.52] = 6.93, p = 0.009).Conclusion: IVA seems to have a greater impact in reducing cyst sizes than IVR in diabetic CME.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241280737","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to compare the effect of intravitreal aflibercept (IVA) and ranibizumab (IVR) on the maximal diameter of the largest intraretinal cyst (mdIRC), indicating chronicity in patients with diabetic cystoid macular edema (CME).

Methods: This retrospective, comparative study included a subgroup of patients from the MARMASIA Study with treatment-naïve diabetic CME who had IVA (IVA group) or IVR (IVR group) on a pro re nata regimen after a loading dose of 3-monthly injections and followed-up for 24 months. Best-corrected visual acuity (logMAR), central macular thickness (CMT, µm), and mdIRC (µm) and their changes during the study period in the IVA and IVR groups were compared.

Results: A total of 175 eyes (65 [37.1%] in IVA and 110 [62.9%] in IVR group) of 113 patients were included in the study analysis. Both groups had statistically significant improvements in BCVA and CMT during the follow-up (p < 0.05 for all), which were comparable between the groups at each time point. However, the mean reduction in mdIRCs was consistently and significantly higher in the IVA group compared to the IVR group at each follow-up examination (F[1, 3.52] = 6.93, p = 0.009).

Conclusion: IVA seems to have a greater impact in reducing cyst sizes than IVR in diabetic CME.

查看原文本刊更多论文

雷尼珠单抗和阿夫利拜因对缩小糖尿病囊样黄斑水肿最大囊肿直径的疗效：MARMASIA研究小组。

目的：本研究旨在比较玻璃体内阿弗利百普（IVA）和雷尼单抗（IVR）对最大视网膜内囊肿（mdIRC）最大直径的影响，这表明糖尿病囊样黄斑水肿（CME）患者的慢性化程度：这项回顾性比较研究纳入了 MARMASIA 研究中的糖尿病囊样黄斑水肿患者亚组，这些患者在接受了 3 个月一次的负荷剂量注射后，按照原方案接受了 IVA（IVA 组）或 IVR（IVR 组）治疗，并随访了 24 个月。比较了 IVA 组和 IVR 组的最佳矫正视力（logMAR）、黄斑中心厚度（CMT，µm）和 mdIRC（µm）及其在研究期间的变化：共有113名患者的175只眼睛（IVA组65只[37.1%]，IVR组110只[62.9%]）被纳入研究分析。在随访期间，两组患者的 BCVA 和 CMT 均有统计学意义的改善（P 结论：IVA 似乎对患者的视力影响更大：在减少糖尿病 CME 的囊肿大小方面，IVA 似乎比 IVR 更有效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.